Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.
| Title | Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50. |
| Publication Type | Journal Article |
| Year of Publication | 2018 |
| Authors | Zarogoulidis, P., Papadopoulos V., Maragouli E., Papatsibas G., Sardeli C., Man Y-G., Bai C., & Huang H. |
| Journal | Transl Lung Cancer Res |
| Volume | 7 |
| Issue | Suppl 1 |
| Pagination | S28-S30 |
| Date Published | 2018 Feb |
| ISSN | 2218-6751 |
| DOI | 10.21037/tlcr.2018.01.04 |
| Alternate Journal | Transl Lung Cancer Res |
| PubMed ID | 29531900 |
| PubMed Central ID | PMC5835639 |
